Monitoring Tumor Response After Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3'-Deoxy-3'-[F]Fluorothymidine PET

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2016 Oct 13

PMID 27730471

Citations 3

Authors

Chun-Yi Wu

Jo-Hsin Tang

Pei-Chia Chan

Jia-Je Li

Ming-Hsien Lin

Chih-Chieh Shen

Ren-Shyan Liu

Hsin-Ell Wang

Affiliations

Soon will be listed here.

Abstract

Purpose: Surgical resection is the standard treatment for localized colorectal cancer, which is the most common type of gastrointestinal cancer. However, over 40 % cases are diagnosed metastasized and apparently inoperable. Systemic chemotherapy provides an alternative to these patients. This study aims to evaluate the therapeutic potential of liposomal doxorubicin (lipoDox) in combination with liposomal vinorelbine (lipoVNB) in a CT-26 colon carcinoma-bearing mouse model.

Procedures: The in vitro cytotoxicity of Dox and VNB on CT-26 cancer cells was determined by MTT and colony formation assays. Mice were subcutaneously inoculated with 2 × 10 of CT-26 cells in the right hind flank. When tumor size reached 200 ± 50 mm, mice were assigned to receive different treatment protocols. The pharmacokinetics, micro single-photon emission computed tomography/x-ray computed tomography imaging, biodistribution, and immunohistochemical staining studies were performed to survey the therapeutic efficacy of each regimen.

Results: Based on the results of pharmacokinetic study, co-administration of lipoDox and lipoVNB did not affect their individual systemic distribution, while lipoDox retained longer in blood than lipoVNB did. Superior tumor growth retardation was observed in the group received lipoDox plus lipoVNB administration (1 mg/kg each, namely DV) than those injected with lipoDox plus VNB (1 mg/kg each, namely DfV). No severe side effects were detected in each group. The tumor-to-muscle ratio (T/M) derived from 3'-dexoy-3'-[F]fluorothymidine ([F]FLT) micro positron emission tomography (PET) images of DV- and DfV-treated mice and the controls on day 7 was 6.88 ± 0.54, 7.50 ± 0.84, and 9.87 ± 0.73, respectively, suggesting that DV is a more efficacious regimen against CT-26 xenografts. The results of proliferating cell nuclear antigen (PCNA) immunohistochemical staining were consistent with those findings obtained from [F]FLT microPET imaging.

Conclusion: This study demonstrated that lipoDox in combination with lipoVNB was more efficacious than clinically used regimen, lipoDox plus VNB, in the treatment of colon carcinoma and [F]FLT-PET is a promising approach in monitoring the treatment outcome at early stage.

Citing Articles

Advances in Drug Targeting, Drug Delivery, and Nanotechnology Applications: Therapeutic Significance in Cancer Treatment.

Ciftci F, Ozarslan A, Kantarci I, Yelkenci A, Tavukcuoglu O, Ghorbanpour M Pharmaceutics. 2025; 17(1).

PMID: 39861768 PMC: 11769154. DOI: 10.3390/pharmaceutics17010121.

Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies.

Hsieh H, Kuo W, Lin J, Chen H, Hsu H, Wu C ACS Omega. 2022; 7(35):31529-31537.

PMID: 36092556 PMC: 9454275. DOI: 10.1021/acsomega.2c04230.

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products.

Cheng X, Yan H, Pang S, Ya M, Qiu F, Qin P Front Chem. 2022; 10:963004.

PMID: 36003616 PMC: 9393238. DOI: 10.3389/fchem.2022.963004.

Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer.

Gong Z, Chen M, Ren Q, Yue X, Dai Z Signal Transduct Target Ther. 2020; 5(1):12.

PMID: 32296050 PMC: 7005157. DOI: 10.1038/s41392-019-0104-3.

References

Cunningham D, Atkin W, Lenz H, Lynch H, Minsky B, Nordlinger B . Colorectal cancer. Lancet. 2010; 375(9719):1030-47. DOI: 10.1016/S0140-6736(10)60353-4. View

Carrato A, Rosell R, Camps C, Anton A, Garcia-Gomez R, Aranda E . Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer. 1997; 17(2-3):261-9. DOI: 10.1016/s0169-5002(97)00029-9. View

Lee W, Chang C, Ho C, Chen L, Wu Y, Chen J . Early detection of tumor response by FLT/microPET Imaging in a C26 murine colon carcinoma solid tumor animal model. J Biomed Biotechnol. 2011; 2011:535902. PMC: 3157890. DOI: 10.1155/2011/535902. View

Lo Y . Phospholipids as multidrug resistance modulators of the transport of epirubicin in human intestinal epithelial Caco-2 cell layers and everted gut sacs of rats. Biochem Pharmacol. 2000; 60(9):1381-90. DOI: 10.1016/s0006-2952(00)00451-2. View

Kao Y, Juliano R . Interactions of liposomes with the reticuloendothelial system. Effects of reticuloendothelial blockade on the clearance of large unilamellar vesicles. Biochim Biophys Acta. 1981; 677(3-4):453-61. DOI: 10.1016/0304-4165(81)90259-2. View

Jaffray M, Buchbinder N, Lutun A, Schneider P, Piquenot J, Vannier J . Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children. Ann Hematol. 2015; 94(8):1401-6. DOI: 10.1007/s00277-015-2362-7. View

Seitz U, Wagner M, Neumaier B, Wawra E, Glatting G, Leder G . Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3'-[(18)F]fluoro-3'-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging. 2002; 29(9):1174-81. DOI: 10.1007/s00259-002-0851-0. View

Swift L, Rephaeli A, Nudelman A, Phillips D, Cutts S . Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res. 2006; 66(9):4863-71. DOI: 10.1158/0008-5472.CAN-05-3410. View

Wang H, Liao A, Deng W, Chang P, Chen J, Chen F . Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model. J Nucl Med. 2004; 45(2):302-8. View

10.

Love R, Leventhal H, Easterling D, Nerenz D . Side effects and emotional distress during cancer chemotherapy. Cancer. 1989; 63(3):604-12. DOI: 10.1002/1097-0142(19890201)63:3<604::aid-cncr2820630334>3.0.co;2-2. View

11.

Tewey K, Rowe T, Yang L, Halligan B, Liu L . Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984; 226(4673):466-8. DOI: 10.1126/science.6093249. View

12.

Been L, Suurmeijer A, Cobben D, Jager P, Hoekstra H, Elsinga P . [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004; 31(12):1659-72. DOI: 10.1007/s00259-004-1687-6. View

13.

Drummond D, Noble C, Guo Z, Hayes M, Park J, Ou C . Improved pharmacokinetics and efficacy of a highly stable nanoliposomal vinorelbine. J Pharmacol Exp Ther. 2008; 328(1):321-30. PMC: 2685908. DOI: 10.1124/jpet.108.141200. View

14.

Wu C, Chou L, Chan P, Ho C, Lin M, Shen C . Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after doxisome(®) treatment. Mol Imaging Biol. 2012; 15(3):326-35. DOI: 10.1007/s11307-012-0604-9. View

15.

Rasey J, Grierson J, Wiens L, Kolb P, Schwartz J . Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002; 43(9):1210-7. View

16.

Watson A, Collins P . Colon cancer: a civilization disorder. Dig Dis. 2011; 29(2):222-8. DOI: 10.1159/000323926. View

17.

Lin Y, Li J, Chang C, Lu Y, Hwang J, Tseng Y . Evaluation of pharmacokinetics of 111In-labeled VNB-PEGylated liposomes after intraperitoneal and intravenous administration in a tumor/ascites mouse model. Cancer Biother Radiopharm. 2009; 24(4):453-60. DOI: 10.1089/cbr.2008.0572. View

18.

Klotz D, Nelson S, Kroboth K, Newton I, Radulescu S, Ridgway R . The microtubule poison vinorelbine kills cells independently of mitotic arrest and targets cells lacking the APC tumour suppressor more effectively. J Cell Sci. 2012; 125(Pt 4):887-95. PMC: 3311929. DOI: 10.1242/jcs.091843. View

19.

Gabizon A, Martin F . Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs. 1997; 54 Suppl 4:15-21. DOI: 10.2165/00003495-199700544-00005. View

20.

Koo S, Wen J, Hillmer A, Cheah P, Tan P, Tan I . Current and emerging surveillance strategies to expand the window of opportunity for curative treatment after surgery in colorectal cancer. Expert Rev Anticancer Ther. 2013; 13(4):439-50. DOI: 10.1586/era.13.14. View